Neuland Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Smallcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories' board approved audited consolidated and standalone financial results for FY25 (year ended March 31, 2025). Consolidated revenue from operations declined to Rs. 1,476.84 crore from Rs. 1,558.58 crore in FY24 (down ~5.2%). Profit after tax fell to Rs. 260.11 crore from Rs. 300.08 crore (down ~13.3%), translating into a lower EPS of Rs. 202.74 vs Rs. 233.89. Results include an exceptional gain of Rs. 76.40 crore from the perpetual lease of an investment property in Nanakramguda, Hyderabad. The board recommended a final dividend of Rs. 12 per share (120% on face value of Rs. 10), subject to shareholder approval. Statutory auditors MSKA & Associates issued an unmodified (clean) opinion on both standalone and consolidated results.
Sharper fall in profit (down ~13%) compared to revenue dip suggests core margin pressure. The hefty dividend (Rs. 12/share) offers shareholder return, though it's largely propped up by an exceptional one-time property gain. Investors should watch whether core API business can recover margins next year. Strong operating cash flow of Rs. 317 crore and low debt-equity ratio keep the balance sheet healthy.